NCT05986786View on ClinicalTrials.gov

Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

April 19, 2024

Study Completion Date

March 21, 2025

Conditions

Chorioretinal Vascular Disease

Interventions

DEVICE

Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule

Patient will receive AVT06 (proposed aflibercept biosimilar) PFS injection

Trial Locations (1)

Unknown

4001, Tbilisi

All Listed Sponsors

lead

Alvotech Swiss AG

INDUSTRY

NCT05986786 - Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease | Biotech Hunter | Biotech Hunter